Virax Biolabs Group (Virax Biolabs Group) Debt-to-Equity : 0.03 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Debt-to-Equity?

Virax Biolabs Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.05 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.13 Mil. Virax Biolabs Group's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $6.33 Mil. Virax Biolabs Group's debt to equity for the quarter that ended in Sep. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Virax Biolabs Group's Debt-to-Equity or its related term are showing as below:

VRAX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13 Med: 0.02 Max: 0.09
Current: 0.03

During the past 4 years, the highest Debt-to-Equity Ratio of Virax Biolabs Group was 0.09. The lowest was -0.13. And the median was 0.02.

VRAX's Debt-to-Equity is ranked better than
80.97% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs VRAX: 0.03

Virax Biolabs Group Debt-to-Equity Historical Data

The historical data trend for Virax Biolabs Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Debt-to-Equity Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

0.02

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial			-0.13	-	0.09	0.02	0.03

Competitive Comparison of Virax Biolabs Group's Debt-to-Equity

For the Biotechnology subindustry, Virax Biolabs Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Debt-to-Equity falls into.

Virax Biolabs Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Virax Biolabs Group's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.146	+	0)	/	9.126
	=	0.02

Virax Biolabs Group's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.05	+	0.132)	/	6.333
	=	0.03

Virax Biolabs Group (NAS:VRAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Virax Biolabs Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.